Wilson Sonsini Goodrich & Rosati advised Goldman Sachs Alternatives on patent matters related to the transaction. Triveni Bio, a biotech company, announced the completion of a...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised MARAbio Systems, Inc. on intellectual property matters related to the transaction. MARAbio Systems, Inc. (MARAbio), a precision immunology company whose...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati represented ImmunityBio in the transaction. ImmunityBio, Inc., a clinical-stage immunotherapy company announced an up to $320 million royalty financing and equity...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini advised Zymeworks on the deal. Zymeworks BC Inc. and Jazz Pharmaceuticals Ireland Ltd. announced that they entered into an exclusive license agreement to develop...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised ABL on the deal. ABL Bio, Inc., a clinical-stage biotech developing bispecific antibody technology for immuno-oncology and neurodegenerative diseases, announced...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Sorriso Pharmaceuticals on the deal. Sorriso Pharmaceuticals, a biotechnology company advancing a pipeline of disease-modifying antibodies for the treatment of...
You must be a Standard 1 Year member to access this content.
Latham & Watkins LLP and Wilson Sonsini Goodrich & Rosati represented Erasca in the transaction. Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on...
You must be a Standard 1 Year member to access this content.
